What is the proper technique and dosage for injecting a small dose of bupivacaine into a tender trigger point in the trapezius muscle?

Trigger Point Injection of Bupivacaine for Trapezius Muscle Pain

For trigger point injection in the trapezius muscle, use bupivacaine 0.25% at a dose of 0.5-1 mL per trigger point, with a maximum total dose not exceeding 2.5 mg/kg (or approximately 175 mg in an average adult without epinephrine). This approach provides effective pain relief for myofascial trigger points while maintaining a safe margin below toxic plasma concentrations.

Dosing and Concentration

The evidence supports using bupivacaine 0.25% concentration for peripheral trigger point injections 1. This concentration provides adequate sensory blockade without excessive motor blockade, which is appropriate for outpatient trigger point therapy.

Maximum Safe Doses:

• Without epinephrine: 175 mg total dose (approximately 70 mL of 0.25% solution) 2
• With epinephrine 1:200,000: 225 mg total dose (approximately 90 mL of 0.25% solution) 2
• Per trigger point: 0.5-1 mL of 0.25% solution 3, 4
• Maximum of 8 trigger points can be safely injected per session 3

For an average 70 kg adult, the weight-based maximum is 2.5 mg/kg = 175 mg without epinephrine 1. This translates to 70 mL of 0.25% bupivacaine (since 0.25% = 2.5 mg/mL).

Technique Considerations

Needle Placement:

• Identify the tender trigger point through palpation
• Use a small gauge needle (typically 25-27 gauge)
• Insert perpendicular to the skin surface
• Advance until you encounter the taut band or trigger point
• Aspirate before injection to avoid intravascular administration 2

Volume per Trigger Point:

Research demonstrates that 0.5-1 mL per trigger point is sufficient 3, 4. Using small volumes (0.5 mL) of 0.25% bupivacaine provides equivalent efficacy to larger volumes while reducing total drug exposure and systemic absorption risk.

Clinical Evidence for Efficacy

Bupivacaine is more cost-effective than botulinum toxin for myofascial pain syndrome, with equivalent pain relief duration and magnitude 3. A randomized controlled trial found no significant difference between 25 units of botulinum toxin A versus 0.5 mL of 0.5% bupivacaine per trigger point in terms of pain reduction, function, or satisfaction.

Ropivacaine causes less injection pain than bupivacaine (VAS 2.5 vs 4.4, P<0.05) 5, making it an alternative if injection discomfort is a concern. However, bupivacaine remains the standard due to widespread availability and extensive safety data.

Bupivacaine and etidocaine are superior to saline for trigger point therapy 4, confirming that the local anesthetic effect contributes to pain relief beyond mechanical disruption of the trigger point alone.

Safety Considerations

Local Anesthetic Systemic Toxicity (LAST):

The toxic plasma threshold for bupivacaine is 2000-4000 ng/mL 6, 7. With proper dosing (≤2.5 mg/kg), peak plasma concentrations remain well below this threshold. The highest reported concentration after appropriate dosing was 374 ng/mL 7, providing a substantial safety margin.

Signs of LAST to Monitor:

• CNS toxicity: perioral numbness, metallic taste, tinnitus, confusion, seizures
• Cardiovascular toxicity: bradycardia, hypotension, arrhythmias, cardiac arrest 6

LAST Treatment Protocol:

If toxicity occurs 6:

1. Stop injection immediately
2. Call for help and alert nearest facility with cardiopulmonary bypass
3. Administer 100% oxygen and secure airway
4. Treat seizures with benzodiazepines (midazolam 0.1-0.2 mg/kg IV)
5. Administer 20% lipid emulsion: 1.5 mL/kg IV bolus over 1 minute, followed by infusion at 0.25 mL/kg/min
6. Repeat bolus once or twice if cardiovascular collapse persists
7. Continue infusion for ≥10 minutes after circulatory stability

Critical Precautions:

• Never exceed 2.5 mg/kg without epinephrine or 3 mg/kg with epinephrine 1, 2
• Always aspirate before injection to avoid intravascular administration
• Use incremental dosing when injecting multiple trigger points 2
• Reduce doses by 30% in elderly or debilitated patients 2
• Avoid rapid injection of large volumes 2

Alternative Considerations

If bupivacaine is unavailable or contraindicated, ropivacaine 0.2% can be used at 0.5-1 mL per trigger point, with a maximum dose of 3 mg/kg 1. Ropivacaine has lower cardiotoxicity than bupivacaine and causes less injection pain 5.

Dry needling (needle insertion without injectate) provides some benefit but is generally less effective than local anesthetic injection 4, 8.

Practical Algorithm

1. Calculate maximum safe dose: Patient weight (kg) × 2.5 mg/kg = maximum mg of bupivacaine
2. Select concentration: Use 0.25% bupivacaine (2.5 mg/mL)
3. Determine volume per trigger point: 0.5-1 mL per point
4. Calculate maximum number of trigger points: Maximum dose (mg) ÷ 2.5 mg/mL ÷ 1 mL per point
5. Prepare equipment: 25-27 gauge needle, syringe with bupivacaine, alcohol prep
6. Inject each trigger point: Palpate, insert needle, aspirate, inject slowly
7. Monitor for 30 minutes post-procedure for signs of LAST